Last reviewed · How we verify
KPI-121 1.0% Ophthalmic Suspension
KPI-121 1.0% Ophthalmic Suspension is a Small molecule drug developed by Kala Pharmaceuticals, Inc.. It is currently in Phase 1 development. Also known as: Loteprednol etabonate 1.0%.
At a glance
| Generic name | KPI-121 1.0% Ophthalmic Suspension |
|---|---|
| Also known as | Loteprednol etabonate 1.0% |
| Sponsor | Kala Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation (PHASE3)
- Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain (PHASE3)
- Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KPI-121 1.0% Ophthalmic Suspension CI brief — competitive landscape report
- KPI-121 1.0% Ophthalmic Suspension updates RSS · CI watch RSS
- Kala Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about KPI-121 1.0% Ophthalmic Suspension
What is KPI-121 1.0% Ophthalmic Suspension?
KPI-121 1.0% Ophthalmic Suspension is a Small molecule drug developed by Kala Pharmaceuticals, Inc..
Who makes KPI-121 1.0% Ophthalmic Suspension?
KPI-121 1.0% Ophthalmic Suspension is developed by Kala Pharmaceuticals, Inc. (see full Kala Pharmaceuticals, Inc. pipeline at /company/kala-pharmaceuticals-inc).
Is KPI-121 1.0% Ophthalmic Suspension also known as anything else?
KPI-121 1.0% Ophthalmic Suspension is also known as Loteprednol etabonate 1.0%.
What development phase is KPI-121 1.0% Ophthalmic Suspension in?
KPI-121 1.0% Ophthalmic Suspension is in Phase 1.
Related
- Manufacturer: Kala Pharmaceuticals, Inc. — full pipeline
- Also known as: Loteprednol etabonate 1.0%
- Compare: KPI-121 1.0% Ophthalmic Suspension vs similar drugs
- Pricing: KPI-121 1.0% Ophthalmic Suspension cost, discount & access